Wang Fen, Wang Shubin, Zhou Qing
Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Guangdong Lung Cancer Institute, South China University of Technology, Guangzhou, China.
Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Department of Oncology, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Peking University Shenzhen Hospital, Shenzhen, China.
Front Oncol. 2020 Oct 20;10:568059. doi: 10.3389/fonc.2020.568059. eCollection 2020.
Immunotherapy has revolutionized lung cancer treatment in the past decade. By reactivating the host's immune system, immunotherapy significantly prolongs survival in some advanced lung cancer patients. However, resistance to immunotherapy is frequent, which manifests as a lack of initial response or clinical benefit to therapy (primary resistance) or tumor progression after the initial period of response (acquired resistance). Overcoming immunotherapy resistance is challenging owing to the complex and dynamic interplay among malignant cells and the defense system. This review aims to discuss the mechanisms that drive immunotherapy resistance and the innovative strategies implemented to overcome it in lung cancer.
在过去十年中，免疫疗法彻底改变了肺癌的治疗方式。通过重新激活宿主的免疫系统，免疫疗法显著延长了一些晚期肺癌患者的生存期。然而，免疫疗法耐药很常见，表现为对治疗缺乏初始反应或临床益处（原发性耐药），或在初始反应期后肿瘤进展（获得性耐药）。由于恶性细胞与防御系统之间复杂而动态的相互作用，克服免疫疗法耐药具有挑战性。本综述旨在探讨导致免疫疗法耐药的机制以及为克服肺癌中的免疫疗法耐药而实施的创新策略。
